Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Specimen Handling 631pembrolizumab 610Magnetic Resonance Spectroscopy 553Carboplatin 450Cisplatin 398Cyclophosphamide 397Biopsy 375Nivolumab 326Paclitaxel 324Gemcitabine 317Radiotherapy 286Bevacizumab 244Dexamethasone 222fludarabine 215Docetaxel 199durvalumab 195venetoclax 188Oxaliplatin 187atezolizumab 184Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 169Radiation 167Doxorubicin 166Radiosurgery 159Ipilimumab 147Etoposide 142Leucovorin 141Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ustekinumab × 90 days × Clear all
NCT06807593 2026-03-05

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡